At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
Lenalidomidedrug
Likely dose
Lenalidomide 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma
In Brief
A Phase 2 clinical trial evaluating Lenalidomide for Adult T-Cell Leukemia-Lymphoma. Completed, enrolled 26 participants across 18 sites.
Detailed Summary
To evaluate the efficacy of lenalidomide in patients with Adult T-cell Leukemia-lymphoma (ATL) who have previously received chemotherapy for ATL.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult T-Cell Leukemia-Lymphoma
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 2012
Enrollment StartNov 2012
Primary CompletionNov 2014
Study CompletionMar 2017
TodayJul 2026
First PostedNov 9, 2012
Enrollment StartNov 12, 2012
Primary CompletionNov 20, 2014
Study CompletionMar 21, 2017
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 13.6 years ago
Interventions
Lenalidomidedrug
25 mg of Lenalidomide administered orally once daily